Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC6999 | D-CPP-ene |
| Potent and competitive NMDA antagonist (Ki = 40 nM). Centrally active following systemic administration. | |
| BCC7001 | GR 159897 |
| A potent, selective, non-peptide, orally active neurokinin NK2 receptor antagonist. Competes for binding of [3H]GR100679 to hNK2-transfected CHO cells with a pKi of 9.5. Inhibits NK2 receptor-mediated contraction of guinea pig trachea with a pA2 of 8.7. Anxiolytic in vivo. | |
| BCC7002 | (-)-Xestospongin C |
| Reported inhibitor of IP3-dependent Ca2+ release. Inhibits bradykinin-induced Ca2+ release in PC12 cells and attenuates PHP-induced IL-2 production in Jurkat T cells. Exhibits no effect on ryanodine receptor-mediated Ca2+ release in PC12 cells. Does not interact with the IP3 binding site. Recently shown to be an ineffective antagonist of IP3-evoked Ca2+ release in IP3 receptor expressing DT40 cells. Cell permeable. | |
| BCC7004 | ARL 67156 trisodium salt |
| Selective NTPDase inhibitor (pIC50 = 4.62 and 5.1 in human blood and rat vas deferens respectively). | |
| BCC7005 | LY 231617 |
| Antioxidant; protects against ischemia-induced neuronal damage in rat models of global and focal cerebral ischemia. Neuroprotective in vitro and in vivo. | |
| BCC7007 | Anisomycin |
| Protein synthesis inhibitor (blocks translation). Potent activator of stress-activated protein kinases (JNK/SAPK) and p38 MAP kinase. Acts as a potent signaling agonist to selectively elicit homologous desensitization of immediate early gene induction (c-fos, fosB, c-jun, junB and junD). | |
| BCC7008 | Ochratoxin A |
| Mycotoxin that increases activity of the endoplasmic reticulum ATP-dependent calcium pump. Induces JNK activation and apoptosis in MDCK-C7 cells at nanomolar concentrations. Stimulates lipid peroxidation. | |
| BCC7012 | (S)-3,4-DCPG |
| Potent, selective mGlu8a agonist (EC50 = 31 nM). Displays > 100-fold selectivity over mGlu1-7 and displays little or no activity at NMDA and kainate receptors. Increases c-Fos expression in stress-related brain areas following systemic administration in mice in vivo. Also potent anticonvulsant in mice in vivo.Caged (S)-3,4-DCPG, (RS)-3,4-DCPG and (R)-3,4-DCPG also available. | |
